Project 3 will be directed towards the origins of BE and response to ablative therapy, and represents an extension of the hypotheses from Projects 1 and 2, specifically that chronic inflammation and activation of stem/progenitor cells are key factors in the development of BE. Data from histopathologic studies in humans and from our L2-IL-1 beta mouse model suggest that CLE (independent of goblet cells) may represent tissue at risk for neoplastic progression. However, there are currently no validated biomarkers of CLE as tissue with neoplastic potential. In patients who progress, endoscopic therapy with radiofrequency ablation (RFA) can eradicate both dysplasia and intestinal metaplasia. We have found that 25-35% of ablated patients develop IM and even dysplasia at the GE junction. We therefore propose to study this patient population as a novel human model for the development of BE through evaluation of biomarkers for recurrent IM. Using this same cohort, we will evaluate pre-treatment markers that predict short- and long-term response to RFA, as the ability to identify non-responders prior to treatment would allow better targeting of resources to those who would predictably respond to the therapy. In order to address these issues, we propose three aims: 1) To determine the site of origin of BE based on gene expression profiles in humans. We will extend the findings from the L2-IL-1beta mouse model to humans by comparing gene expression profiles of Barrett's and cardia tissue in BE patients and controls. We will evaluate specific markers of stem cell activation as well as new biologically-based markers identified by genomic analyses, as potential new biomarkers for CLE and BE;2) To determine whether stem cell markers predict recurrence of BE after ablation therapy. We hypothesize that the recurrence of IM after ablative therapy is secondary to stem cell differentiation into an intestinal phenotype in the cardia, and that central obesity may impact this process;3) To determine biomarkers which can predict response to ablation therapy in patients with BE. We will prospectively follow a large cohort of BE patients with HGD/EAC who undergo RFA. We will determine if pi6 status impacts efficacy will explore the possibility that epigenetic changes represent potentially modifiable predictors of non-response to therapy.

Public Health Relevance

This Project is designed to identify biologically-based and clinically-useful biomarkers of tissue at risk for neoplastic progression as well as of response to ablation therapy. These results will result in improved risk stratification in BE and better targeting of resources for patients who are candidates for ablative therapy, while simultaneously providing key information regarding the origins of Barrett's esophagus.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163004-03
Application #
8535699
Study Section
Special Emphasis Panel (ZCA1-SRLB-1)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
3
Fiscal Year
2013
Total Cost
$248,278
Indirect Cost
$49,422
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Fecteau, Ryan E; Kong, Jianping; Kresak, Adam et al. (2016) Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia. JAMA Oncol 2:1333-1339
Critchley-Thorne, Rebecca J; Duits, Lucas C; Prichard, Jeffrey W et al. (2016) A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus. Cancer Epidemiol Biomarkers Prev 25:958-68
Bansal, Ajay; Gupta, Vijayalaxmi; Wang, Kenneth (2016) MicroRNA Expression Signatures During Malignant Progression From Barrett's Esophagus. J Cell Biochem 117:1288-95
Chan, Daniel K; Leggett, Cadman L; Wang, Kenneth K (2016) Diagnosing gastrointestinal illnesses using fecal headspace volatile organic compounds. World J Gastroenterol 22:1639-49
Schellnegger, Raphael; Quante, Anne; Rospleszcz, Susanne et al. (2016) Goblet Cell Ratio in Combination with Differentiation and Stem Cell Markers in Barrett Esophagus Allow Distinction of Patients with and without Esophageal Adenocarcinoma. Cancer Prev Res (Phila) :
Kong, Jianping; Whelan, Kelly A; Laczkó, Dorottya et al. (2016) Autophagy levels are elevated in barrett's esophagus and promote cell survival from acid and oxidative stress. Mol Carcinog 55:1526-1541
Snider, Erik J; Freedberg, Daniel E; Abrams, Julian A (2016) Potential Role of the Microbiome in Barrett's Esophagus and Esophageal Adenocarcinoma. Dig Dis Sci 61:2217-25
Pattison, Amanda M; Blomain, Erik S; Merlino, Dante J et al. (2016) Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins. Infect Immun 84:3083-91
Small, Aaron J; Sutherland, Scott E; Hightower, Jessica S et al. (2015) Comparative risk of recurrence of dysplasia and carcinoma after endoluminal eradication therapy of high-grade dysplasia versus intramucosal carcinoma in Barrett's esophagus. Gastrointest Endosc 81:1158-66.e1-4
Stachler, Matthew D; Taylor-Weiner, Amaro; Peng, Shouyong et al. (2015) Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet 47:1047-55

Showing the most recent 10 out of 43 publications